Found 9 matching trials
Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First Line PHASE3 This study is designed to evaluate the efficacy and safety of first-line tr...
Show More Location
Gemeinschaftspraxis für Hämatologie und Onkologie
Learn More & Join Trial
Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer PHASE1 This phase Ib/II trial studies the side effects and best dose of ribociclib...
Show More Status
Active Not Recruiting
Location
UCLA / Jonsson Comprehensive Cancer Center
Learn More & Join Trial
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) PHASE3 This is a Phase 3, open-label, randomized, clinical trial evaluating the ef...
Show More Location
City of Hope Medical Center
Learn More & Join Trial
Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers PHASE1 To characterize the safety and tolerability, identify recommended doses and...
Show More Location
Massachusetts General Hospital Massachusetts General Hospital
Learn More & Join Trial
CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDO PHASE2 Prospective, open label, multicenter, group sequential response adaptive ra...
Show More Location
U.O. Oncologia Medica, P.O. Bellaria-Maggiore
Learn More & Join Trial
Cyclin Dependant Kinase 4/6 (CDK4/6) Inhibitors as a Second Line Treatment in Metastatic Breast Cancer Patients PHASE3 Breast cancer is the commonest malignancy among females and one of the lead...
Show More Location
Oncology center mansoura university
Learn More & Join Trial
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer PHASE2 The majority of patients (pts) with breast cancer have hormone receptor pos...
Show More Status
Active Not Recruiting
Location
University of Miami
Learn More & Join Trial
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors PHASE1 Phase I: Characterize safety and tolerability of ECI830 as a single agent a...
Show More Location
University of California LA
Learn More & Join Trial
Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype PHASE2 This trial studies a type of advanced breast cancer defined as hormone rece...
Show More Location
Medizinische Universität Graz
Learn More & Join Trial